Private company
Kindred Biosciences, Inc.
American pharmaceutical preparations company based in Burlingame. Summary from the record
Last updated Oct 21, 2026.
Overview
- IndustryPharmaceutical Preparations2
- HeadquartersBurlingame, United States2
- Legal formCorporation2
- LEI549300WFSYEUFAX5EB172
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Harvard Business Services, Inc., 19958 Lewes, United States2
- Registered withDivision of Corporations, Department of State, 52187872
Corporate structure
Kindred Biosciences, Inc. sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Kindred Biosciences, Inc.
- Point72 Asset Management, L.P. Filed SC 13G/A on Kindred Biosciences, Inc., latest Feb 14, 2022
- Kindred Biosciences, Inc. Burlingame, California, United States
- Ameriprise Financial Stake · Minneapolis, Minnesota, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.
Leadership
Who has led Kindred Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerRichard Chin Dec 11, 2013 to Aug 30, 20213
- PresidentDenise Bevers Oct 24, 2018 to Jan 24, 20204
- PresidentRichard Chin Dec 11, 2013 to Oct 3, 20183
- Chief financial officerDenise Bevers Jan 24, 2018 to Jan 24, 20185
- Chief financial officerWendy Wee Jul 28, 2017 to Aug 30, 20216
- Chief financial officerStephen S. Galliker Dec 11, 2013 to Apr 28, 20147
- Chief operating officerDenise Bevers Dec 11, 2013 to Jan 24, 20208
Board members and other officers (12)
- Chief Scientific OfficerHangjun Zhan Jan 24, 2018 to Aug 30, 20219
- Chief Commercial OfficerSelby Blake Hawley Apr 2, 2014 to Apr 4, 201410
- Senior Vice PresidentStephen Sundlof Dec 11, 2013 to Jan 25, 201711
- Board memberLyndon Lien Feb 9, 2021 to Aug 30, 202112
- Board memberJoseph S. McCracken Apr 24, 2018 to Aug 30, 202113
- Board memberDenise Bevers Oct 24, 2018 to Aug 30, 20214
- Board memberHerbert D. Montgomery Apr 15, 2016 to Aug 30, 202114
- Board memberErnest Mario Dec 11, 2013 to Jan 22, 202115
- Board memberErvin Veszpremi Dec 11, 2013 to Aug 30, 202116
- Board memberOleg Nodelman Dec 11, 2013 to Sep 30, 201417
- Board memberRaymond Townsend Dec 11, 2013 to Aug 30, 202118
- Board memberRichard Chin Dec 11, 2013 to Aug 30, 20213
Timeline
- Dec 11, 2013New chief executive Richard Chin becomes CEO3
Filings
1 filings to the SEC since October 2021: 1 large holders. The latest 1:
- Feb 14, 2022SC 13G/A SCHEDULE 13G (AMENDMENT NO. 1) EDGAR
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Point72 Asset Management, L.P.SC 13G/A, 1 filing Feb 14, 202219
Stakes it holds
Kindred Biosciences, Inc. has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).
- Ameriprise FinancialSC 13G/A Feb 14, 202220
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4SEC EDGARDenise Bevers, President
- 5
- 6SEC EDGARWendy Wee, Chief financial officer
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARLyndon Lien, Board member
- 13SEC EDGARJoseph S. McCracken, Board member
- 14SEC EDGARHerbert D. Montgomery, Board member
- 15SEC EDGARErnest Mario, Board member
- 16SEC EDGARErvin Veszpremi, Board member
- 17SEC EDGAROleg Nodelman, Board member
- 18SEC EDGARRaymond Townsend, Board member
- 19
- 20